摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-氯喹唑啉-4-甲酸乙酯 | 1092352-52-7

中文名称
2-氯喹唑啉-4-甲酸乙酯
中文别名
2-氯-4-喹唑啉羧酸乙酯;2-氯喹唑啉-4-羧酸乙酯
英文名称
ethyl 2-chloroquinazoline-4-carboxylate
英文别名
——
2-氯喹唑啉-4-甲酸乙酯化学式
CAS
1092352-52-7
化学式
C11H9ClN2O2
mdl
——
分子量
236.658
InChiKey
KLQNJTKSLRIEAW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    355.3±25.0 °C(Predicted)
  • 密度:
    1.341

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.18
  • 拓扑面积:
    52.1
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2933990090
  • 危险性防范说明:
    P261,P280,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H332,H335

反应信息

点击查看最新优质反应信息

文献信息

  • ALKYNYL ALCOHOLS AND METHODS OF USE
    申请人:Genentech, Inc.
    公开号:US20150057260A1
    公开(公告)日:2015-02-26
    The invention relates to compounds of Formula (0): wherein A 1 -A 8 , R 4 and R 5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
    该发明涉及具有以下结构的化合物(0):其中A1-A8,R4和R5分别具有如本文所述的含义。 公式(0)的化合物及其药物组成物在治疗观察到NF-kB信号不受欢迎或过度激活的疾病和紊乱中是有用的。
  • [EN] ALKYNYL ALCOHOLS AND METHODS OF USE<br/>[FR] ALCOOLS ALCYNYLIQUES ET LEURS PROCÉDÉS D'UTILISATION
    申请人:HOFFMANN LA ROCHE
    公开号:WO2015025026A1
    公开(公告)日:2015-02-26
    The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
    该发明涉及以下式的化合物(0):其中A1-A8,R4和R5分别具有如本文所述的含义。该式(0)的化合物及其药物组合物在治疗观察到NF-kB信号不良或过度激活的疾病和紊乱中是有用的。
  • Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
    申请人:BioCryst Pharmaceuticals, Inc.
    公开号:US11021458B2
    公开(公告)日:2021-06-01
    Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    公开了式 I 和 II 的化合物及其药学上可接受的盐和原药,它们是补体系统的抑制剂。还提供了包含此类化合物的药物组合物,以及使用这些化合物和组合物治疗或预防以补体系统活性异常为特征的疾病或病症的方法。
  • Facile approaches toward the synthesis of N4-monosubstituted quinazolin-2,4-diamines
    作者:Tarek Mohamed、Praveen P.N. Rao
    DOI:10.1016/j.tetlet.2015.10.096
    日期:2015.12
    The amination of quinazoline-based heterocyclics is of significant interest due to its privileged structure and application in the development of bioactive compound libraries, as well as in the synthesis of readily convertible building blocks. The current approaches generally result in low yields, utilize harsh conditions, and/or rely on expensive catalysts. After examining three different approaches to synthesize N4-monosubstituted quinazolin-2,4-diamines, we developed an efficient and mild synthetic method to prepare quinazolin-2,4-diamines in 80-85% yields. (C) 2015 Elsevier Ltd. All rights reserved.
  • SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS
    申请人:Biocryst Pharmaceuticals, Inc.
    公开号:EP3687506A1
    公开(公告)日:2020-08-05
查看更多